Important Notice for Neumora Therapeutics, Inc. (NMRA) Shareholders: Potential Securities Class Action Lawsuit
New York, NY – The Gross Law Firm, a leading securities litigation law firm, notifies investors that a securities class action lawsuit has been filed against Neumora Therapeutics, Inc. (NMRA) on behalf of shareholders who purchased or acquired the securities of Neumora Therapeutics, Inc. (NMRA) between March 1, 2023, and November 23, 2024. The lawsuit was filed in the United States District Court for the Southern District of New York and alleges violations of the Securities Exchange Act of 1934.
Background:
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapeutic candidates for the treatment of neurological disorders. The Company’s lead product candidate, NM-001, is a proprietary, orally administered cannabinoid receptor type 1 agonist for the treatment of pain and spasticity in patients with multiple sclerosis.
Class Period and Allegations:
The class period for this lawsuit is from March 1, 2023, to November 23, 2024. The complaint alleges that during the class period, Neumora Therapeutics, Inc. made false and misleading statements and failed to disclose material information to investors, including:
- Inadequate data supporting the safety and efficacy of NM-001
- Insufficient clinical trial data to support the initiation of Phase 3 trials
- Lack of regulatory approval for NM-001
- Lack of commercialization plans for NM-001
Impact on Shareholders:
As a result of these alleged false and misleading statements, Neumora Therapeutics, Inc. (NMRA) securities traded at artificially inflated prices during the class period, causing significant harm to investors. If you purchased or acquired the securities of Neumora Therapeutics, Inc. (NMRA) during the class period, you may be entitled to compensation.
Worldwide Impact:
The securities class action lawsuit against Neumora Therapeutics, Inc. (NMRA) has significant implications for the biopharmaceutical industry as a whole. The case highlights the importance of transparency and accurate disclosure in the securities markets. It also serves as a reminder that companies must provide investors with truthful and complete information regarding their clinical trials, regulatory approvals, and commercialization plans.
Lead Plaintiff Appointment:
If you purchased or acquired the securities of Neumora Therapeutics, Inc. (NMRA) during the class period and wish to serve as lead plaintiff, you must apply to the Court by May 6, 2025. Shareholders who wish to learn more about the case and how they can participate can contact The Gross Law Firm at [email protected] or call 212-504-1450.
About The Gross Law Firm:
The Gross Law Firm is a leading securities litigation law firm based in New York, NY. The firm represents institutional and individual investors who have suffered securities losses due to corporate wrongdoing. The Gross Law Firm’s securities attorneys have recovered billions of dollars for their clients.
Conclusion:
The securities class action lawsuit against Neumora Therapeutics, Inc. (NMRA) serves as a reminder to investors to carefully evaluate the information provided by companies and to seek legal recourse when necessary. If you purchased or acquired Neumora Therapeutics, Inc. (NMRA) securities during the class period and believe you have been harmed as a result of the company’s alleged false and misleading statements, contact The Gross Law Firm today to learn more about your legal rights and potential recovery.
The Gross Law Firm represents its clients on a contingency basis, meaning there are no upfront costs or fees. The firm is committed to fighting for the rights of investors and ensuring that companies are held accountable for their actions.
